PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GLP Weigh Loss
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Diversification

Asset Allocation


NVO 15%LLY 15%AMGN 13%AZN 11%REGN 10%ALNY 10%TEVA 10%MCK 8%VKTX 7%HIMS 1%EquityEquity
PositionCategory/SectorTarget Weight
ALNY
Alnylam Pharmaceuticals, Inc.
Healthcare
10%
AMGN
Amgen Inc.
Healthcare
13%
AZN
AstraZeneca PLC
Healthcare
11%
HIMS
Hims & Hers Health, Inc.
Consumer Defensive
1%
LLY
Eli Lilly and Company
Healthcare
15%
MCK
McKesson Corporation
Healthcare
8%
NVO
Novo Nordisk A/S
Healthcare
15%
REGN
Regeneron Pharmaceuticals, Inc.
Healthcare
10%
TEVA
Teva Pharmaceutical Industries Limited
Healthcare
10%
VKTX
Viking Therapeutics, Inc.
Healthcare
7%

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in GLP Weigh Loss , comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced every 3 months.


100.00%150.00%200.00%250.00%300.00%350.00%NovemberDecember2025FebruaryMarchApril
234.44%
75.66%
GLP Weigh Loss
Benchmark (^GSPC)
Portfolio components

The earliest data available for this chart is Sep 13, 2019, corresponding to the inception date of HIMS

Returns By Period


YTD1M6M1Y5Y*10Y*
^GSPC
S&P 500
-10.18%-6.79%-9.92%6.35%14.12%9.63%
GLP Weigh Loss -8.10%-8.85%-25.25%-12.99%20.65%N/A
NVO
Novo Nordisk A/S
-31.39%-23.22%-50.02%-51.73%14.55%9.74%
MCK
McKesson Corporation
22.45%5.43%37.20%33.43%40.55%12.70%
LLY
Eli Lilly and Company
8.99%0.29%-8.19%16.40%42.57%30.27%
AMGN
Amgen Inc.
7.25%-12.26%-12.40%6.25%7.01%8.16%
REGN
Regeneron Pharmaceuticals, Inc.
-20.84%-14.48%-43.08%-37.12%0.71%1.63%
AZN
AstraZeneca PLC
4.60%-9.80%-12.42%0.60%8.69%9.72%
ALNY
Alnylam Pharmaceuticals, Inc.
-0.32%-17.22%-20.74%62.43%11.26%7.07%
TEVA
Teva Pharmaceutical Industries Limited
-38.07%-15.22%-23.96%6.14%6.97%-13.59%
VKTX
Viking Therapeutics, Inc.
-40.51%-17.31%-63.62%-62.25%33.63%N/A
HIMS
Hims & Hers Health, Inc.
12.61%-21.64%22.93%128.82%22.65%N/A
*Annualized

Monthly Returns

The table below presents the monthly returns of GLP Weigh Loss , with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20250.28%5.51%-8.48%-5.09%-8.10%
20249.12%20.66%4.58%-0.95%1.59%5.33%-2.61%9.66%-7.62%-3.08%-6.85%-8.27%19.24%
2023-0.82%-3.95%9.30%6.34%-0.98%1.07%-0.76%11.14%-2.21%-1.04%7.03%4.58%32.37%
2022-7.14%3.62%10.02%-2.75%2.50%-0.46%2.84%0.38%-1.22%10.98%5.45%3.22%29.40%
202110.53%-3.94%0.34%0.33%3.41%7.94%3.58%6.25%-5.41%2.70%-1.34%4.28%31.25%
2020-1.69%0.40%-0.97%12.97%6.67%1.99%-1.33%-2.18%-1.37%-8.70%6.29%1.59%12.75%
2019-1.39%6.68%11.84%2.35%20.41%

Expense Ratio

GLP Weigh Loss has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.


The portfolio doesn't include any funds that charge management fees.

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GLP Weigh Loss is 6, meaning it’s performing worse than 94% of other portfolios on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GLP Weigh Loss is 66
Overall Rank
The Sharpe Ratio Rank of GLP Weigh Loss is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of GLP Weigh Loss is 55
Sortino Ratio Rank
The Omega Ratio Rank of GLP Weigh Loss is 55
Omega Ratio Rank
The Calmar Ratio Rank of GLP Weigh Loss is 66
Calmar Ratio Rank
The Martin Ratio Rank of GLP Weigh Loss is 88
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for Portfolio, currently valued at -0.60, compared to the broader market-4.00-2.000.002.00
Portfolio: -0.60
^GSPC: 0.24
The chart of Sortino ratio for Portfolio, currently valued at -0.69, compared to the broader market-6.00-4.00-2.000.002.004.00
Portfolio: -0.69
^GSPC: 0.47
The chart of Omega ratio for Portfolio, currently valued at 0.92, compared to the broader market0.400.600.801.001.201.401.60
Portfolio: 0.92
^GSPC: 1.07
The chart of Calmar ratio for Portfolio, currently valued at -0.43, compared to the broader market0.002.004.006.00
Portfolio: -0.43
^GSPC: 0.24
The chart of Martin ratio for Portfolio, currently valued at -0.96, compared to the broader market0.005.0010.0015.0020.00
Portfolio: -0.96
^GSPC: 1.08

Portfolio components
Sharpe ratioSortino ratioOmega ratioCalmar ratioMartin ratio
NVO
Novo Nordisk A/S
-1.25-1.920.75-0.87-1.81
MCK
McKesson Corporation
1.201.611.271.363.36
LLY
Eli Lilly and Company
0.370.791.100.541.11
AMGN
Amgen Inc.
0.270.581.080.330.77
REGN
Regeneron Pharmaceuticals, Inc.
-1.32-1.860.77-0.68-1.28
AZN
AstraZeneca PLC
0.040.201.030.040.07
ALNY
Alnylam Pharmaceuticals, Inc.
1.102.241.291.475.12
TEVA
Teva Pharmaceutical Industries Limited
0.090.541.070.100.28
VKTX
Viking Therapeutics, Inc.
-0.78-1.220.86-0.82-1.57
HIMS
Hims & Hers Health, Inc.
1.091.891.251.844.19

The current GLP Weigh Loss Sharpe ratio is -0.22. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Compared to the broad market, where average Sharpe ratios range from 0.22 to 0.77, this portfolio's current Sharpe ratio places it in the bottom 25%. This suggests that it may not be performing as well in terms of risk-adjusted returns compared to many other portfolios. The lower performance could be due to either lower returns, higher volatility, or a combination of both. This might indicate that the portfolio requires some fine-tuning. You can use the Portfolio Optimization tool to find an allocation that maximizes the Sharpe ratio.

Use the chart below to compare the Sharpe ratio of GLP Weigh Loss with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
-0.60
0.24
GLP Weigh Loss
Benchmark (^GSPC)
Portfolio components

Dividends

Dividend yield

GLP Weigh Loss provided a 1.24% dividend yield over the last twelve months.


TTM20242023202220212020201920182017201620152014
Portfolio1.24%1.09%0.93%1.00%1.11%1.29%1.33%1.52%1.98%2.35%1.50%1.63%
NVO
Novo Nordisk A/S
2.78%1.68%1.00%1.20%1.34%1.86%2.14%2.47%2.12%3.93%1.31%1.96%
MCK
McKesson Corporation
0.39%0.47%0.50%0.54%0.72%0.95%1.16%1.32%0.80%0.80%0.53%0.46%
LLY
Eli Lilly and Company
0.64%0.67%0.78%1.07%1.23%1.75%1.96%1.95%2.46%2.77%2.37%2.84%
AMGN
Amgen Inc.
3.29%3.45%2.96%2.95%3.13%2.78%2.41%2.71%2.65%2.74%1.95%1.53%
REGN
Regeneron Pharmaceuticals, Inc.
0.16%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
AZN
AstraZeneca PLC
2.26%2.27%2.15%2.14%2.40%2.80%2.81%3.61%3.95%5.01%4.06%3.98%
ALNY
Alnylam Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
TEVA
Teva Pharmaceutical Industries Limited
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.49%3.75%2.07%2.38%
VKTX
Viking Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
HIMS
Hims & Hers Health, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-35.00%-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%NovemberDecember2025FebruaryMarchApril
-29.69%
-14.02%
GLP Weigh Loss
Benchmark (^GSPC)
Portfolio components

Worst Drawdowns

The table below displays the maximum drawdowns of the GLP Weigh Loss . A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GLP Weigh Loss was 34.49%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current GLP Weigh Loss drawdown is 26.75%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-34.49%Sep 3, 2024150Apr 8, 2025
-21.37%Feb 13, 202027Mar 23, 202018Apr 17, 202045
-17.68%Jul 21, 202073Oct 30, 202053Jan 19, 2021126
-13.74%Apr 11, 202247Jun 16, 202237Aug 10, 202284
-13.13%Nov 5, 202156Jan 26, 202236Mar 18, 202292

Volatility

Volatility Chart

The current GLP Weigh Loss volatility is 12.71%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%NovemberDecember2025FebruaryMarchApril
12.71%
13.60%
GLP Weigh Loss
Benchmark (^GSPC)
Portfolio components

Diversification

Asset Correlations Table

The table below displays the correlation coefficients between the individual components of the portfolio, the entire portfolio, and the chosen benchmark.

HIMSMCKTEVAVKTXALNYAZNNVOLLYREGNAMGN
HIMS1.000.070.220.280.260.120.170.150.140.13
MCK0.071.000.250.150.120.230.210.290.290.37
TEVA0.220.251.000.300.260.240.210.210.230.25
VKTX0.280.150.301.000.370.210.250.230.250.23
ALNY0.260.120.260.371.000.220.230.250.350.26
AZN0.120.230.240.210.221.000.450.370.330.38
NVO0.170.210.210.250.230.451.000.480.340.29
LLY0.150.290.210.230.250.370.481.000.350.38
REGN0.140.290.230.250.350.330.340.351.000.47
AMGN0.130.370.250.230.260.380.290.380.471.00
The correlation results are calculated based on daily price changes starting from Sep 16, 2019
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab